Drilldown: Medicines
Appearance
Medicines > onset
:
BP and symptomatic LUTS improvement within 1-2 weeks
or
First bowel movement within 1-2 hours 
:
BP and symptomatic LUTS improvement within 1-2 weeks
or
First bowel movement within 1-2 hours 
Use the filters below to narrow your results.
[[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]] (2) ·
[[:Category:Antihypertensives|Antihypertensive]] (2) ·
[[:Category:Bowel_preparation_agents|Bowel preparation agent]] (1) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (2) ·
[[:Category:Osmotic_laxatives|Osmotic laxative]] (1)
None (1) ·
'"`UNIQ--vote-00000054-QINU`"' The clinical efficacy endpoint is adequate visualization at colonoscopy, scored by the Boston Bowel Preparation Scale'"`UNIQ--ref-00000055-QINU`"'. (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
4 L oral solution (GoLYTELY-class) split-dose: 2 L evening before, 2 L morning of procedure; low-volume products (MoviPrep, Plenvu) use 1-2 L with required clear-fluid intake (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1)
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not absorbed; generally considered acceptable when bowel prep is required<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 3 results in range #1 to #3.

